efzimfotase alfa - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Platinum Equity to acquire Energy Distribution Partners after 45 acquisitions and threefold EBITDA growth

Infographic showing Senores Pharmaceuticals Limited’s ₹43 crore manufacturing expansion in India and the United States, nearly 25% quarterly revenue growth, improved operating margins and a 14.4% share-price decline over two trading sessions.

Senores Pharmaceuticals (SENORES) targets 3.2bn annual manufacturing units, yet 50% to 70% utilisation raises a bigger question

People Inc added 320 employees this year. Why is it still cutting 195 jobs?

Infographic showing Aspen Neuroscience pricing its Nasdaq IPO at $15 per share, highlighting sasineprocel’s planned move into Phase 3 testing for Parkinson’s disease, operating runway into the second half of 2028 and the likelihood of additional capital needs.

Aspen Neuroscience (ASPE) prices $140.6m IPO at $15 as Parkinson’s therapy enters pivotal development phase

Representative image of pharmaceutical research, drug pipeline analytics and commercial growth trends, reflecting AstraZeneca’s Q1 2026 results and its push to sustain oncology, rare disease and respiratory medicine momentum toward its 2030 revenue ambition.

Read More

Pharma Industry News

AstraZeneca Q1 2026 results: Can oncology and rare disease growth keep AZN’s 2030 ambition on track?

AstraZeneca’s growth engine is firing, but pricing pressure and launch risk still loom. Can oncology and rare disease carry AZN to 2030?

April 29, 2026

web analytics